[artículo] 
inPsychiatric Clinics of North America > Año 2005 - Vol. 28 No. 4 (Diciembre) . - pp. 941-983

Título :	Pharmacologic interventions for psychosis and agitation in neurodegenerative diseases : evidence about efficacy and safety
Tipo de documento:	texto impreso
Autores:	Daniel Weintraub, Autor ; Ira R. Katz, Autor
Fecha de publicación:	2020
Artículo en la página:	pp. 941-983
Idioma :	Inglés (eng) Idioma original : Inglés (eng)
Palabras clave:	Agentes antipsicóticos, Enfermedades neurodegenerativas, Agitación psicomotora, Trastornos psicóticos.
Resumen:	Despite a significant body of research in this area, there are critical gaps in the evidence base on the treatment of the psychotic and behavioral symptoms associated with Alzheimer's disease and vascular dementia. This problem has been exacerbated by recent FDA warnings on the risks of increased CVAEs and mortality with atypical antipsychotic treatment, without the release of the scientific evidence on which these warnings are based.
Link:	./index.php?lvl=notice_display&id=24642

[artículo] Pharmacologic interventions for psychosis and agitation in neurodegenerative diseases : evidence about efficacy and safety [texto impreso] / Daniel Weintraub, Autor ; Ira R. Katz, Autor . - 2020 . - pp. 941-983.
Idioma : Inglés (eng) Idioma original : Inglés (eng)
in Psychiatric Clinics of North America > Año 2005 - Vol. 28 No. 4 (Diciembre) . - pp. 941-983

Palabras clave:	Agentes antipsicóticos, Enfermedades neurodegenerativas, Agitación psicomotora, Trastornos psicóticos.
Resumen:	Despite a significant body of research in this area, there are critical gaps in the evidence base on the treatment of the psychotic and behavioral symptoms associated with Alzheimer's disease and vascular dementia. This problem has been exacerbated by recent FDA warnings on the risks of increased CVAEs and mortality with atypical antipsychotic treatment, without the release of the scientific evidence on which these warnings are based.
Link:	./index.php?lvl=notice_display&id=24642